DÄ internationalArchiveReferences

Review article

Ovarian Cancer

Dtsch Arztebl Int 2011; 108(38): 635-41. DOI: 10.3238/arztebl.2011.0635

Burges, A; Schmalfeldt, B

1.Krebs in Deutschland 2003 – 2004. Häufigkeiten und Trends. 6th revised edition. Robert-Koch-Institut (ed.) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (ed.). Berlin 2008.
2.Heintz AP, et al.: Carcinoma of the ovary. FIGO 6th anual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006; 95 (Suppl 1): 161–92. CrossRef MEDLINE
3.du Bois A, Rochon J, Lamparter C, Pfisterer J für die AGO-Organkommission Ovar: Ovarialkarzinom – Versorgungsstruktur und -qualität in Deutschland 2001–2004. Der Frauenarzt 2005; 46(7): 60–567.
4.Partridge E, et al.: Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009; 113(4): 775–82. MEDLINE
5.Rebbeck TR, Kauff ND, Domchek SM: Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101(2): 80–7. CrossRef MEDLINE
6.Kauff ND, et al.: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008; 26(8): 1331–7. CrossRef MEDLINE
7.Casey MJ, et al.: Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol 2005; 97(2): 457–67. CrossRef MEDLINE
8.Olivier RI, et al.: Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 2004; 90(8): 1492–7. CrossRef MEDLINE
9.Collaborative Group on Epidemiological Studies of Ovarian Cancer, ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet 2008; (371): 303–14. MEDLINE
10.Morch LS, et al.: Hormone therapy and ovarian cancer. JAMA 2009; 302(3): 298–305. CrossRef MEDLINE
11.Kinkel K, et al.: Indeterminate ovarian mass at US: incremental value of second imaging test for characterization – meta-analysis and Bayesian analysis. Radiology 2005; 236(1): 85–94. CrossRef MEDLINE
12.Salani R, et al.: Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 2008; 108(2): 271–5. CrossRef MEDLINE
13.du Bois A, et al.: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 2009; 115(6): 1234–44. CrossRef MEDLINE
14.Trimbos JB, et al.: Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst 2003; 95(2): 113–25. CrossRef MEDLINE
15.Bristow RE, et al.: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20(5): 1248–59. CrossRef MEDLINE
16.Eisenhauer EL, et al.: The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 2006; 103(3): 1083–90. CrossRef MEDLINE
17.Aletti GD, et al.: Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol 2006; 100(2): 283–7. CrossRef MEDLINE
18.Bristow RE, et al.: Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999; 72(3): 278–87. CrossRef MEDLINE
19.Dowdy SC, et al.: Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma. Gynecol Oncol 2008; 109(2): 303–7. CrossRef MEDLINE
20.Panici PB, et al.: Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005; 97(8): 560–6. CrossRef MEDLINE
21.Covens A, et al.: Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 2002; 85(1): 71–80. CrossRef MEDLINE
22.Robinson WR, et al.: Clinical trial participation is associated with improved outcome in women with ovarian cancer. Int J Gynecol Cancer 2009; 19(1): 124–8. CrossRef MEDLINE
23.Piso P, Ghali N, Dahlke MH, et al.: Die intraoperative hypertherme intraperitoneale Chemotherapie als Therapieoption beim Ovarialkarzinom – Entwicklungen der letzten Jahre. Geburtshilfe und Frauenheilkunde 2007; 67(12): 1317–23. CrossRef
24.du Bois A, Ewald-Riegler N, du Bois O, Harter P: Borderline tumors of the ovary – a systematic review. GebFra 2009; 69(9): 807–33.